117 related articles for article (PubMed ID: 22686341)
1. Analytical methods for dissolution testing of nanosized drugs.
Jünemann D; Dressman J
J Pharm Pharmacol; 2012 Jul; 64(7):931-43. PubMed ID: 22686341
[TBL] [Abstract][Full Text] [Related]
2. In-vitro dissolution methods for controlled release parenterals and their applicability to drug-eluting stent testing.
Seidlitz A; Weitschies W
J Pharm Pharmacol; 2012 Jul; 64(7):969-85. PubMed ID: 22686343
[TBL] [Abstract][Full Text] [Related]
3. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
[TBL] [Abstract][Full Text] [Related]
4. Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®.
Willmann S; Thelen K; Lippert J
J Pharm Pharmacol; 2012 Jul; 64(7):997-1007. PubMed ID: 22686345
[TBL] [Abstract][Full Text] [Related]
5. Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles.
Juenemann D; Jantratid E; Wagner C; Reppas C; Vertzoni M; Dressman JB
Eur J Pharm Biopharm; 2011 Feb; 77(2):257-64. PubMed ID: 21074611
[TBL] [Abstract][Full Text] [Related]
6. Experimental determination of the diffusion boundary layer width of micron and submicron particles.
Galli C
Int J Pharm; 2006 Apr; 313(1-2):114-22. PubMed ID: 16529883
[TBL] [Abstract][Full Text] [Related]
7. Turbidimetric measurement and prediction of dissolution rates of poorly soluble drug nanocrystals.
Crisp MT; Tucker CJ; Rogers TL; Williams RO; Johnston KP
J Control Release; 2007 Feb; 117(3):351-9. PubMed ID: 17239469
[TBL] [Abstract][Full Text] [Related]
8. Nanosizing--oral formulation development and biopharmaceutical evaluation.
Kesisoglou F; Panmai S; Wu Y
Adv Drug Deliv Rev; 2007 Jul; 59(7):631-44. PubMed ID: 17601629
[TBL] [Abstract][Full Text] [Related]
9. [The importance of micronization in the design of dosage forms I. Theoretical and biopharmaceutical aspects].
Antal I
Acta Pharm Hung; 2006; 76(2):95-103. PubMed ID: 17094668
[TBL] [Abstract][Full Text] [Related]
10. Mathematical modeling of drug dissolution.
Siepmann J; Siepmann F
Int J Pharm; 2013 Aug; 453(1):12-24. PubMed ID: 23618956
[TBL] [Abstract][Full Text] [Related]
11. Dissolution and coarsening of polydisperse, polymorph drug particles liberated from a disintegrating finished dosage form: Theoretical considerations.
Horkovics-Kovats S
Eur J Pharm Sci; 2016 Aug; 91():265-77. PubMed ID: 27155254
[TBL] [Abstract][Full Text] [Related]
12. Overcoming sink limitations in dissolution testing: a review of traditional methods and the potential utility of biphasic systems.
Phillips DJ; Pygall SR; Cooper VB; Mann JC
J Pharm Pharmacol; 2012 Nov; 64(11):1549-59. PubMed ID: 23058042
[TBL] [Abstract][Full Text] [Related]
13. A Review: Pharmaceutical and Pharmacokinetic Aspect of Nanocrystalline Suspensions.
Shah DA; Murdande SB; Dave RH
J Pharm Sci; 2016 Jan; 105(1):10-24. PubMed ID: 26580860
[TBL] [Abstract][Full Text] [Related]
14. Dissolution testing of oral modified-release dosage forms.
Garbacz G; Klein S
J Pharm Pharmacol; 2012 Jul; 64(7):944-68. PubMed ID: 22686342
[TBL] [Abstract][Full Text] [Related]
15. Biorelevant in-vitro performance testing of orally administered dosage forms.
Reppas C; Vertzoni M
J Pharm Pharmacol; 2012 Jul; 64(7):919-30. PubMed ID: 22686340
[TBL] [Abstract][Full Text] [Related]
16. A Refined Thin-Film Model for Drug Dissolution Considering Radial Diffusion - Simulating Powder Dissolution.
Salish K; So C; Jeong SH; Hou HH; Mao C
Pharm Res; 2024 May; 41(5):947-958. PubMed ID: 38589647
[TBL] [Abstract][Full Text] [Related]
17. Regulatory aspects of modified release dosage forms: special cases of dissolution testing using the flow-through system.
Möller H; Wirbitzki E
Boll Chim Farm; 1993 Apr; 132(4):105-15. PubMed ID: 8333916
[TBL] [Abstract][Full Text] [Related]
18. A crescent-shaped spindle for improved dissolution testing.
Qureshi SA
Pharmeur Bio Sci Notes; 2009 Oct; 2009(1):55-65. PubMed ID: 20144452
[TBL] [Abstract][Full Text] [Related]
19. Characterization of an active pharmaceutical ingredient by its dissolution properties: amoxicillin trihydrate as a model drug.
Horkovics-Kovats S
Chemotherapy; 2004 Nov; 50(5):234-44. PubMed ID: 15528889
[TBL] [Abstract][Full Text] [Related]
20. What is a suitable dissolution method for drug nanoparticles?
Heng D; Cutler DJ; Chan HK; Yun J; Raper JA
Pharm Res; 2008 Jul; 25(7):1696-701. PubMed ID: 18320295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
